This anti-CD3 antibody can induce a sustained state of antigenspecific nonresponsiveness in unprimed human T cells. High concentration of soluble anti-CD3 antibody can condition T cells to become anergic in response to allogeneic MHC.
| Inventor | Institute |
|---|---|
| Claudio Anasetti | Fred Hutchinson Cancer Center |
| Cat. #: | 161669 |
|---|---|
| Tool sub type: | Primary antibody |
| Cancer types: | Blood cancer |
| Research Fields: | Immunology |
| Application: | Flow cytometry |
| Target: | CD3/T-cell receptor(TCR) complex: CD3ε, one CD3γ, one CD3δ, one CD3ζ |
| Reactivity: | human |
| Clone: | BC3 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Anasetti et al. 1990. Journal of Experimental Medicine. 172(6):1691-700. PMID: 2147949 |
| Product description: | This anti-CD3 antibody can induce a sustained state of antigenspecific nonresponsiveness in unprimed human T cells. High concentration of soluble anti-CD3 antibody can condition T cells to become anergic in response to allogeneic MHC. |
|---|---|
| Isotype: | IgG2b |
| Immunogen: | 2 x 10^6 PHA |
| Target background: | CD3ε is a 20 kD chain of the CD3/T-cell receptor (TCR) complex which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T-cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK-T cells, and some thymocytes. Antigen recognition by human T cells is mediated by the α/β polymorphic chains of the TCR, noncovalently associated on the cell surface with a group of five invariant polypeptides which collectively represent the CD3 complex responsible for signal transduction . Binding of an antibody to TCR or to CD3 can block T cell responses not merely by steric hindrance of TCR but also by altering cellular function. |
|---|
| Storage conditions: | The antibody solution should be stored undiluted between 2° C and 8° C. Please note the storage condition for this antibody has been changed from -20° C to between 2° C and 8° C. |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Anasetti et al.1990.Journal of Experimental Medicine.172(6):1691-700.PMID: 2147949 |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.